摘要
目的:观察玻璃体腔注射Bevacizumab联合复合式小梁切除术,全视网膜激光光凝综合治疗新生血管性青光眼的临床疗效。方法:对21例21只眼药物不能控制的新生血管性青光眼,先行玻璃体腔注射Bevacizumab0.1ml(2.5mg),7～10d后行复合式小梁切除术,前房形成稳定后行全视网膜激光光凝。结果:平均随访11个月,17例视力无变化,4例视力稍有提高,虹膜新生血管注药后16例3d消失,5例新生血管变细,5～7d消失。1、3、6个月平均眼压为(16.70±2.01)mmHg、(17.20±1.85)mmHg、(20.50±2.03)mmHg,与术前相比眼压降低,差异有统计学意义(P<0.05)。其中,19例眼压在正常范围,2例加点噻吗心胺眼液眼压接近正常。所有患者头痛、眼胀痛症状消失。结论:Bevacizumab在新生血管青光眼治疗中具有积极的作用,Bevacizumab玻璃体腔注射联合复合式小梁切除术全视网膜激光光凝为临床治疗新生血管性青光眼提供了新的切实有效的综合治疗方法。
Objective：To observe the clinical effect of intravitreal injection of Bevacizumab combined with trabeculectomy and panretinal photocoagulation for the treatment of neovascular glaucoma（NVG）.Methods：21 cases（21 eyes） of NVG were managed with intravitreal Bevacizumab combined with trabeculectomy（7-10 days after injection）.And panretinal photocoagulation when the anterior chamber were formed.Results：The average follow-up period was 11 months,visual acuity remained unchanged in 17 cases and slightly increased in 4 cases.Iris neovascularization was disappeared in 16 cases 3 days after injection.In the other 5 cases it was regressed and disappeared in 5-7 days.After 1,3,6 months the average intraocular pressures（IOP） were（16.70 ±2.01） mm Hg,（17.20±1.85） mm Hg,（20.50±2.03） mm Hg respectively,which had significant difference compared with preoperative IOP（P0.05）.The IOP was controled in 19 cases.In the other 2 cases it was closed to normal added with Timolol.Headache and eye expansion were disappeared in all the cases.Conclusion：Intravitreal Bevacizumab has a positive effect in the treatment of neovascular glaucoma.Intravitreal injection of Bevacizumab combined with trabeculectomy and panretinal photocoagulation is effective for the treatment of NVG.
出处
《中国医药导报》
CAS
2010年第27期15-17,共3页
China Medical Herald
